Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ: DMAA · Real-Time Price · USD
10.25
+0.02 (0.20%)
Aug 13, 2025, 4:00 PM - Market closed
Company Description
Drugs Made In America Acquisition Corp. does not have significant operations.
It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Drugs Made In America Acquisition Corp.
| Country | United States |
| Founded | 2024 |
| IPO Date | Jan 28, 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Lynn Stockwell |
Contact Details
Address: 1 East Broward Boulevard, Suite 700 Fort Lauderdale, Florida 33301 United States | |
| Phone | 954 870 3099 |
| Website | dmaacorp.com |
Stock Details
| Ticker Symbol | DMAA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0002028614 |
| ISIN Number | KYG2847J1040 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Lynn Stockwell | Chief Executive Officer and Executive Chairman |
| Glenn Charles Worman | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | SCHEDULE 13D | Filing |
| Feb 25, 2025 | 8-K | Current Report |